How to launch a UK sexual health and STI testing telehealth service in 2026

Sexual health is one of the most established UK telehealth verticals and one of the most patient-loved — the discretion and convenience of remote care suit a category where in-person attendance often carries social cost. Launching a sexual health telehealth service in 2026 means handling home-testing kits under MHRA IVD regulation, treating common STIs with clear pathways, navigating the NHS-private boundary on PrEP, and meeting public-health obligations around notifiable diseases. This piece is the operator's launch brief.

Why sexual health telehealth has scaled — and where NHS leaves gaps

Sexual health is one of the longest-established remote care categories in the UK. The patient case for telehealth is direct: discretion, convenience, and the avoidance of in-person clinic visits for asymptomatic screening. Demand has grown as NHS sexual health services have been pressured — waiting times for in-person sexual health clinics have lengthened in many regions, opening private telehealth opportunity.

Brands operating well in this category meet a real patient need with a service that is fast, discreet, and clinically rigorous. Brands operating poorly create reputational risk for the broader telehealth sector. The category is reputationally as well as operationally sensitive — patient trust is the moat.

Clinical scope — testing, treatment, PrEP, contraception

Sexual health telehealth in the UK typically covers four service lines. STI testing via home test kits sent to laboratory, with results delivered through the platform. Treatment of common STIs (chlamydia, gonorrhoea where uncomplicated, herpes management, common genitourinary conditions) where treatment can be safely prescribed remotely. PrEP (pre-exposure prophylaxis) prescribing for HIV prevention. Contraception including emergency contraception, oral contraceptives, and increasingly long-acting reversible options coordinated with in-person provision.

Each service line has different operational profiles, different clinician credentialing requirements, and different regulatory considerations. Brands typically launch with two of the four and add the others as the operation matures.

Home testing kits — UK IVD regulation and operational realities

In-vitro diagnostic (IVD) devices including STI home test kits are regulated by MHRA under UK IVD Regulations. Suppliers and platforms distributing IVDs must ensure CE / UKCA marking, instructions for use compliance, and appropriate post-market surveillance. Self-sample kits (patient collects, ships to lab) are common; self-test kits (patient performs test at home, reads result) are typically used for HIV self-testing under specific MHRA-approved products.

Operationally: kit assembly and dispatch needs to handle sterility, temperature where relevant, and return-shipping logistics. Laboratory partnership for sample processing is foundational — turnaround time is a major patient experience driver. Result delivery must be clinically appropriate: positive results for serious conditions should not arrive by email alone with no clinician contact pathway.

PrEP prescribing and the NHS-private interplay

PrEP (pre-exposure prophylaxis) for HIV prevention is available on the NHS for eligible patients via sexual health clinics. Private PrEP prescribing via telehealth has scaled to meet demand that the NHS service has not fully absorbed. The clinical pathway requires: baseline screening for HIV and STIs, kidney function assessment, ongoing monitoring at three-to-six month intervals, and continuing patient education on adherence and risk reduction.

Private PrEP services that skip the baseline screening or the ongoing monitoring are clinically and regulatorily exposed. The treatment is well-evidenced; the operational discipline around it is what distinguishes good services from problematic ones.

Partner notification and the public-health dimension

Notifiable diseases under the Health Protection (Notification) Regulations 2010 require statutory reporting — including syphilis and certain other STIs in defined circumstances. Telehealth services must include the reporting infrastructure: identify reportable cases, route through to the responsible clinician, ensure reports are made to the relevant local Health Protection Team.

Partner notification — informing past sexual partners of potential exposure — is part of sexual health best practice and is supported by UK Health Security Agency frameworks. Telehealth services should support patients with partner notification options including self-notification tools, clinician-supported notification, and signposting to local NHS services where complex partner-notification work is needed.

Regulatory posture and the discretion expectation

Sexual health telehealth sits under standard UK regulators (CQC for the clinical service in England, MHRA for medicines and IVDs, GPhC for dispensing, ICO for data). The category-specific watch points: sexual health data is sensitive special-category data under UK GDPR Article 9 and requires explicit lawful-basis documentation, advertising prescription medicines is prohibited (covers most STI treatments) under HMR 2012, and discretion in communication design is operationally expected by patients.

Email subject lines, postal packaging, payment descriptors, and the visible patient-portal language all contribute to whether the service delivers on the discretion expectation. Patients who feel exposed by careless operational design do not return, do not refer, and sometimes complain publicly. Discretion is a product feature.

How PExpo supports sexual health brand launches

PExpo's brand model includes the clinical workflow for STI testing, treatment, PrEP, and contraception pathways, a UK prescriber network with sexual health experience, GPhC-compliant dispensing for the relevant medicine ranges, IVD-compliant test kit fulfilment, and laboratory partnership for sample processing. The data infrastructure handles the special-category sensitivity throughout.

Launching a UK sexual health brand in 2026 is faster through partnership than from scratch because the IVD logistics, laboratory partnerships, and discretion-focused operational design are pre-built. See our brand model page for the full operational scope or our clinic model page if you are a clinic adding sexual health to an existing service line.

Discretion is a product feature. Patients who feel exposed by careless operational design do not return, do not refer, and sometimes complain publicly.

Launching a UK sexual health and STI testing telehealth service in 2026 is a real opportunity — patient demand is high, NHS gaps are real, and the operational template is established. The operators who handle IVD regulation properly, run PrEP with full clinical discipline, meet public-health reporting obligations, and design for discretion build sustainably. See our brand model page for the white-label option, our clinic model page for adding sexual health inside an existing clinic, and our pricing page for the commercial structure.

Frequently asked questions